Literature DB >> 24047086

Cardiac toxicity of some echinocandin antifungals.

Kayla R Stover1, Jerry M Farley, Patrick B Kyle, John D Cleary.   

Abstract

BACKGROUND: Unexplained cardiovascular decompensation has been observed during central venous administration of some echinocandins.
OBJECTIVE: The purpose of this study was to assess cardiac toxicity associated with the echinocandins.
METHODS: Isolated rat hearts (Langendorff model) were perfused with anidulafungin (ANID), caspofungin (CASP), or micafungin (MICA) at exposures of 1, 4, and 10 times therapeutic concentrations. Changes in left ventricular contractility with experimental exposure were compared to control, and histologic and transmission electron microscopy (TEM) examinations of tissue were performed.
RESULTS: Mean concentrations of ANID (10 - 80 µg/ml) and CASP (6 - 48 µg/ml) were associated with significant decreases in contractility (-77.1 ± 9.4% and -40.6 ± 15.6%, respectively; p < 0.05). MICA was associated with an increase in contractility (13.6 ± 2.8%, p = NS). On TEM, samples exposed to ANID and CASP had enlarged mitochondria and disintegrating myofibrils. Samples exposed to MICA showed some enlarged mitochondria.
CONCLUSION: Mean concentrations of ANID and CASP were associated with statistically significant decreases in left ventricular contractility at concentrations that may be achievable in humans after peripheral administration, while MICA caused no change. TEM studies suggest this may be a result of mitochondrial damage. Caution may be warranted with central administration of these agents to patients with preexisting cardiac dysfunction.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24047086     DOI: 10.1517/14740338.2013.829036

Source DB:  PubMed          Journal:  Expert Opin Drug Saf        ISSN: 1474-0338            Impact factor:   4.250


  11 in total

Review 1.  [Strategies for antifungal treatment failure in intensive care units].

Authors:  C Arens; M Bernhard; C Koch; A Heininger; D Störzinger; T Hoppe-Tichy; M Hecker; B Grabein; M A Weigand; C Lichtenstern
Journal:  Anaesthesist       Date:  2015-09       Impact factor: 1.041

Review 2.  New facets of antifungal therapy.

Authors:  Ya-Lin Chang; Shang-Jie Yu; Joseph Heitman; Melanie Wellington; Ying-Lien Chen
Journal:  Virulence       Date:  2016-11-07       Impact factor: 5.882

3.  Hemodynamic changes in surgical intensive care unit patients undergoing echinocandin treatment.

Authors:  Christian Koch; Emmanuel Schneck; Christoph Arens; Melanie Markmann; Michael Sander; Michael Henrich; Markus A Weigand; Christoph Lichtenstern
Journal:  Int J Clin Pharm       Date:  2019-11-21

4.  Caspofungin Modulates Ryanodine Receptor-Mediated Calcium Release in Human Cardiac Myocytes.

Authors:  Christian Koch; Jennifer Jersch; Emmanuel Schneck; Fabian Edinger; Hagen Maxeiner; Florian Uhle; Markus A Weigand; Melanie Markmann; Michael Sander; Michael Henrich
Journal:  Antimicrob Agents Chemother       Date:  2018-10-24       Impact factor: 5.191

5.  Cardiac effects of echinocandins after central venous administration in adult rats.

Authors:  Christian Koch; Florian Uhle; Matthias Wolff; Christoph Arens; Astrid Schulte; Ling Li; Bernd Niemann; Michael Henrich; Susanne Rohrbach; Markus A Weigand; Christoph Lichtenstern
Journal:  Antimicrob Agents Chemother       Date:  2014-12-29       Impact factor: 5.191

6.  Safety and Efficacy of Intermittent Intravenous Administration of High-Dose Micafungin.

Authors:  Dionysis Neofytos; Yao-Ting Huang; Kimberly Cheng; Nina Cohen; Miguel-Angel Perales; Juliet Barker; Sergio Giralt; Ann Jakubowski; Genovefa Papanicolaou
Journal:  Clin Infect Dis       Date:  2015-12-01       Impact factor: 9.079

7.  Cardiac Effects of Echinocandins in Endotoxemic Rats.

Authors:  Christian Koch; Matthias Wolff; Michael Henrich; Markus A Weigand; Christoph Lichtenstern; Florian Uhle
Journal:  Antimicrob Agents Chemother       Date:  2015-10-26       Impact factor: 5.191

8.  Cardiac Safety of High-dose Micafungin.

Authors:  Kayla R Stover; John D Cleary
Journal:  J Pharmacol Pharmacother       Date:  2017 Jul-Sep

9.  Enhanced Efficacy of Thiosemicarbazone Derivative-Encapsulated Fibrin Liposomes against Candidiasis in Murine Model.

Authors:  Azmat Ali Khan; Amer M Alanazi; Nawaf Alsaif; Nasser Algrain; Tanveer Ahmad Wani; Mashooq Ahmad Bhat
Journal:  Pharmaceutics       Date:  2021-03-04       Impact factor: 6.321

10.  Effects of tetracycline on myocardial infarct size in obese rats with chemically-induced colitis.

Authors:  Yury Yu Borshchev; Sarkis M Minasian; Inessa Yu Burovenko; Victor Yu Borshchev; Egor S Protsak; Natalia Yu Semenova; Olga V Borshcheva; Michael M Galagudza
Journal:  PLoS One       Date:  2019-11-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.